Drug intelligence / Profile preview

AD-2281

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral (tablet)

Overview

AD-2281 is a small molecule drug developed by Addpharma for the treatment of primary hypercholesterolemia. It is being investigated as part of a fixed-dose combination with another compound, AD-2282, targeting patients with elevated cholesterol levels. The precise mechanism of action has not been publicly disclosed, but it falls under the class of antihyperlipidaemics and is intended to lower cholesterol as part of metabolic and endocrinological disease management. As of June 2025, its highest development phase is Phase 3 clinical trials in patients with primary hypercholesterolemia[1][2][3][4].

Targets

CETP

Beyond the preview

Go deeper on AD-2281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2281.

Explore the full profile